• Single-Dose Indometacin Sodium for Acute Postoperative Pain

  2026-07-24

  This Cochrane review rigorously evaluates the efficacy and safety of single-dose oral indometacin sodium for treating acute postoperative pain. The analysis provides critical quantitative insights into pain reduction outcomes, informing best practices for NSAID use in clinical pain management and experimental research.

• Vemurafenib in Melanoma: Mechanisms, Resistance, and Next St

  2026-07-23

  This thought-leadership article explores the mechanistic foundations and translational research strategies surrounding Vemurafenib (PLX4032, RG7204) in BRAF-mutant melanoma. Integrating multi-omics findings, it dissects resistance networks—especially ARID1A-driven adaptations—and provides protocol guidance for researchers seeking to model, dissect, and overcome therapeutic resistance in advanced melanoma.

• Novel 3-Dehydroteasterone Derivatives: Structure–Activity In

  2026-07-23

  This study introduces a new class of 3-dehydroteasterone derivatives featuring 23,24-dinorcholanic side chains and benzoate groups at C-22, systematically evaluating their plant growth regulatory activity. The findings clarify how specific structural modifications influence bioactivity in classical plant assays, advancing the rational design of brassinosteroid analogs for research.

• Cyanine 5-dCTP: Fluorescent Labeling for Advanced DNA Synthe

  2026-07-22

  Empower your DNA labeling and detection workflows with Cyanine 5-dCTP, a high-purity fluorescent nucleotide triphosphate optimized for enzymatic synthesis and imaging. Integrate this reagent to boost signal sensitivity, workflow efficiency, and experimental reproducibility across PCR, DNA sequencing, and advanced nucleic acid detection assays.

• BIBR 1532: Applied Telomerase Inhibitor Workflows & Optimiza

  2026-07-22

  BIBR 1532 enables precise and reproducible telomerase inhibition for advanced cancer research, including apoptosis induction and synergy studies. This guide distills experimental best practices, troubleshooting, and protocol enhancements to maximize data reliability and translational impact.

• AM251: Precision CB1 Receptor Antagonist for Cannabinoid Res

  2026-07-21

  AM251, available from APExBIO, enables unmatched selectivity and potency for dissecting CB1 receptor function in neuropharmacology, metabolic, and cell signaling studies. Its robust nanomolar affinity and well-characterized pharmacology empower advanced experimental workflows, especially when troubleshooting complex endocannabinoid mechanisms or modeling obesity.

• Practical Guide to Using the LDH Cytotoxicity Assay Kit (K22

  2026-07-21

  The LDH Cytotoxicity Assay Kit enables researchers to quantify cell damage and cytotoxicity by measuring lactate dehydrogenase release from compromised cell membranes. This non-radioactive kit is best used for bulk cell death assessment in cancer or neurodegenerative disease models, but is not suited for detailed mechanistic apoptosis analysis or subcellular localization studies.

• EZ Cap™ Cas9 mRNA (m1Ψ): Enhancing Genome Editing Precision

  2026-07-20

  EZ Cap™ Cas9 mRNA (m1Ψ) delivers superior mRNA stability, immune evasion, and translation efficiency for CRISPR-Cas9 genome editing in mammalian systems. Its Cap1 structure and m1Ψ modification minimize off-target effects and streamline experimental workflows, setting a new standard for high-fidelity, reproducible gene editing.

• Ajugol Mitigates Gouty Arthritis via PI3K/AKT/mTOR Inhibitio

  2026-07-20

  This study demonstrates that ajugol alleviates acute gouty arthritis by suppressing the PI3K/AKT/mTOR pathway, enhancing mitophagy, and reducing chondrocyte pyroptosis. The findings clarify the mechanistic basis for targeting mitochondrial homeostasis in inflammatory cartilage damage, with implications for translational research on regulated cell death.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Technical Applicati

  2026-07-19

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody offers a reliable solution for sensitive, specific detection of goat IgG primary antibodies in fluorescence-based assays, including ICC/IF, IHC, flow cytometry, and ELISA. It should be used only as a secondary antibody for goat IgG detection, not for non-goat primaries or direct antigen labeling.

• Lumiracoxib: Selective COX-2 Inhibitor in Muscle Injury Assa

  2026-07-18

  Lumiracoxib empowers researchers with precision in dissecting inflammatory and vascular responses in muscle injury models, especially those involving tissue ischemia and regeneration. Its unique solubility profile and high COX-2 selectivity enable reproducible, high-sensitivity assays across complex workflows.

• Sulfachloropyridazine Shapes Cecal Microbiota in E. tenella

  2026-07-17

  This study provides the first integrated analysis of how sulfachloropyridazine and ethanamizuril, alone or in combination, modulate the cecal microbiota and metabolomic landscape in chickens acutely infected with Eimeria tenella. The findings reveal drug-specific effects on both microbial taxa and metabolic profiles, informing future research on poultry coccidiosis intervention and microbiome monitoring.

• Evaluating Sulfamonomethoxine Toxicity in Aquatic Organisms

  2026-07-17

  This study investigates the acute and chronic toxicity of the veterinary sulfonamide antibiotic sulfamonomethoxine (SMM) across five representative aquatic species from different trophic levels. The work provides quantitative toxicity thresholds and demonstrates the heightened sensitivity of microalgae, emphasizing the need for rigorous environmental monitoring and informed aquaculture management.

• Rosiglitazone (Brl-49653) in PPARγ Research: Protocols & Pit

  2026-07-16

  Rosiglitazone (Brl-49653) is the benchmark synthetic thiazolidinedione PPARγ agonist for dissecting adipogenesis, insulin sensitivity, and metabolic remodeling in cell and animal models. This guide delivers stepwise protocols, troubleshooting strategies, and critical insights from recent advances—empowering reproducible, next-generation type II diabetes research.

• LY2228820: Bridging Anti-Inflammatory and Anti-Angiogenic Re

  2026-07-16

  Explore how LY2228820, a selective p38 MAP kinase inhibitor, is redefining translational research at the intersection of inflammation and angiogenesis. This thought-leadership article for APExBIO unpacks the mechanistic rationale, evidence-backed utility, and strategic guidance for leveraging LY2228820 in advanced anti-inflammatory and cancer studies. Building on recent breakthroughs in airway stent technology and integrating scenario-driven best practices, the discussion empowers researchers to accelerate discovery from bench to bedside.

447 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page